{
  "authorized_claims": [
    {
      "market": "EFSA",
      "framework_reference": "Reg 432/2012",
      "claim_verbatim": "Protein contributes to a growth in muscle mass.",
      "authorization_date": "2012",
      "conditions": "Reg 1924/2006 art 10(2) + Annex: claim may only be used for food which is at least a \"source of protein\" — ≥ 12% of energy value provided by protein"
    },
    {
      "market": "EFSA",
      "framework_reference": "Reg 432/2012",
      "claim_verbatim": "Protein contributes to the maintenance of muscle mass.",
      "authorization_date": "2012",
      "conditions": "Reg 1924/2006 art 10(2) + Annex: claim may only be used for food which is at least a \"source of protein\" — ≥ 12% of energy value provided by protein"
    },
    {
      "market": "EFSA",
      "framework_reference": "Reg 432/2012",
      "claim_verbatim": "Protein contributes to the maintenance of normal bones.",
      "authorization_date": "2012",
      "conditions": "Reg 1924/2006 art 10(2) + Annex: claim may only be used for food which is at least a \"source of protein\" — ≥ 12% of energy value provided by protein"
    },
    {
      "market": "ANVISA",
      "framework_reference": "IN 28/2018 Anexo V alegação funcional",
      "claim_verbatim": "As proteínas auxiliam na formação dos músculos e ossos.",
      "authorization_date": "2018",
      "conditions": "IN 28/2018 Anexo V: alegação restrita aos suplementos cuja quantidade de proteína e perfil de aminoácidos essenciais atendam os Anexos III + VII"
    }
  ],
  "slug": "rice-protein",
  "name": "Rice Protein (Brown Rice Protein Isolate)",
  "alternate_names": [
    "Brown rice protein isolate",
    "Oryza sativa protein",
    "Rice protein concentrate"
  ],
  "mechanism": [
    "Plant protein with low lysine (limiting amino acid) but moderate leucine",
    "mTORC1 / muscle protein synthesis activation at sufficiently high doses (≥ 24-48 g)",
    "Hypoallergenic profile relative to dairy and soy alternatives"
  ],
  "target": [
    "Skeletal muscle protein synthesis",
    "Plant-based dietary protein adequacy",
    "Common allergen avoidance"
  ],
  "use_case": [
    "plant-based diet protein adequacy",
    "dairy / soy allergen avoidance",
    "high-dose blending with pea for complete amino acid profile",
    "sarcopenia prevention"
  ],
  "body_system": [
    "MUSCULO",
    "METABOLISM"
  ],
  "evidence_tier": "B",
  "evidence_anchor_pmid_count": 1,
  "dosage_range": "48 g / day post-exercise produced strength, performance and lean-body-mass gains equivalent to whey at the same dose over 8 weeks (Joy 2013 PMID 23782948 Nutrition Journal RCT in resistance-trained males); 25-30 g typical commercial serving sizes have less robust direct evidence at the single-dose level",
  "safety_notes": "Inorganic arsenic content in rice-based supplements is a watchpoint — choose products with arsenic disclosure / third-party tested batches; lysine-limiting profile is best addressed by blending with pea protein",
  "regulatory": {
    "fda": "GRAS · DSHEA dietary supplement · no specific health claim · qualifies for 21 CFR 101.79 \"good source of protein\" (≥ 10% DV) when serving size meets the threshold",
    "efsa": "Authorized protein claims (Reg 432/2012) for muscle mass + bone maintenance available when food source provides ≥ 12% energy from protein",
    "anvisa": "RDC 243/2018 dietary supplement · IN 28/2018 Anexo V alegação funcional verbatim: \"As proteínas auxiliam na formação dos músculos e ossos.\" (Anexo III ≥ 8,4 g/dia adultos ≥ 19 anos · Anexo VII proteína de referência AAE/g)"
  },
  "ingredient_hub_url": "https://asxan.ai/ingredients/rice-protein/",
  "related_goal_slugs": [
    "athletic-performance",
    "weight-management"
  ],
  "related_lifestyle_slugs": [
    "plant-based",
    "athletic-performance"
  ],
  "last_evidence_review": "2026-06-04",
  "schema_version": "nc-public-v0.2",
  "api_version": "nc-public-v0.3",
  "_meta": {
    "last_evidence_review": "2026-06-04",
    "ip_axes_disclosed": {
      "public_axes": [
        "mechanism",
        "target",
        "use_case",
        "body_system",
        "evidence_tier",
        "dosage_range",
        "safety_notes",
        "regulatory",
        "authorized_claims"
      ],
      "ip_axes_not_exposed": [
        "proprietary_formula_ratios",
        "clinical_protocol_internals",
        "rnd_pipeline_compounds",
        "supplier_specific_grade_specifications",
        "unpublished_endpoint_data"
      ],
      "rationale": "asxan.ai surfaces the educational, evidence-tier-disclosed slice. Formula composition, clinical-protocol internals, and RnD pipeline data are intentionally outside this public surface."
    }
  }
}